Results 11 to 20 of about 34,204 (229)
Primary Cardiac Burkitt’s Lymphoma- A Deadlock [PDF]
Journal of Clinical and Diagnostic Research, 2023 Burkitt’s lymphoma is a high-grade, extremely aggressive form of B-cell non Hodgkin lymphoma with a very fast replication time (tumour doubling time of around 25 hours). The three forms of Burkitt’s lymphoma are documented which include endemic, sporadic,
Vinay Praveen Ayyala +4 more
doaj +1 more source
Clinical Case Reports, 2021 Primary effusion lymphoma (PEL) is a kind of malignant lymphoma that develops without a tumor mass. A fluid smear is of no use for the diagnosis of miscellaneous condition. Repeated cell‐block smear with immunostaining is useful for the diagnosis of PEL.
Yosuke Sazumi +3 more
doaj +1 more source
Primary Effusion Lymphoma: A Clinicopathologic Perspective [PDF]
Cancers, 2022 Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the peritoneum, pleural space, and the pericardium.
Diamone Gathers +5 more
openaire +2 more sources
Haematologica, 2009 Human herpesvirus 8 (HHV-8)-associated primary effusion lymphoma is a rare non-Hodgkin’s lymphoma often associated with Epstein-Barr virus (EBV) infection. Mutations in TP53, PTEN, PIK3CA, CTNNB1/β-catenin genes and deletion of CDKN2A-ARF (p14ARF-p16NK4a
Emmanuelle Boulanger +3 more
doaj +1 more source
Clinical features of cardiac lymphoma: an analysis of 37 cases
Journal of International Medical Research, 2021 Objective To summarize the clinical and pathological features of patients with cardiac lymphoma. Methods The general conditions, clinical features, pathological types, and prognostic indices of 37 patients with cardiac lymphoma treated in our hospital ...
Yu Zhao +4 more
doaj +1 more source
Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future [PDF]
, 2015 Constitutively activated prosurvival pathways render cancer cells addicted to their effects. Consequently they turn out to be the Achilles’ heels whose inhibition can be exploited in anticancer therapy.
CIRONE, Mara +6 more
core +4 more sources
Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death [PDF]
, 2017 BACKGROUND: Apigenin is a flavonoid widely distributed in plant kingdom that exerts cytotoxic effects against a variety of solid and haematological cancers.
Cirone, Mara +5 more
core +3 more sources
Primary Effusion Lymphoma [PDF]
The American Journal of Pathology, 2014 CME Accreditation Statement: This activity (“ASIP 2014 AJP CME Program in Pathogenesis”) has been planned and implemented in accordance with the Essential Areas andpolicies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and theAmerican Society for
Annunziata Gloghini +6 more
openaire +1 more source
The zebrafish xenograft platform-A novel tool for modeling KSHV-associated diseases [PDF]
, 2019 Kaposi\u27s sarcoma associated-herpesvirus (KSHV, also known as human herpesvirus-8) is a gammaherpesvirus that establishes life-long infection in human B lymphocytes.
Berman, Jason N +12 more
core +2 more sources
Primary Effusion Lymphoma Presenting As Parapneumonic Pleural Effusion
Cureus, 2022 Primary effusion lymphoma (PEL) is a rare form of high-grade non-Hodgkin's lymphoma that usually occurs in patients with compromised immunity or human immunodeficiency virus (HIV) infection. PEL is a B-cell lymphoma that principally presents as effusions without a tumor mass.
Gujarathi, Rahul +4 more
openaire +2 more sources